Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics director Zach Scheiner resigns; board shrinks to six members

Neutral Impact 2 of 5 leadership Written later

LENZ Therapeutics said director Zach Scheiner resigned from its Board and all committees effective immediately, on June 30, 2026, and that the resignation was not due to any disagreement with the company. The board reduced its size to six and appointed Jeff George to the audit committee, which now consists of Shelley Thunen, Frederic Guerard, and Jeff George.

Key points

  • Zach Scheiner resigned from the Board and all committees effective immediately, notified on June 30, 2026.
  • The filing states the resignation was not the result of any dispute or disagreement on operations, policies or practices.
  • The Board decreased its size to six members following the resignation.
  • Jeff George was appointed to the Audit Committee on June 30, 2026.

The filing

CompanyLENZ Therapeutics, Inc. (LENZ)
Form8-K, current report
Filed with the SECJul 2, 2026, 5:00 PM ET
Accession number0001815776-26-000046

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.